Medtronic Plc

Medtronic reported its strongest annual revenue growth in a decade with Q4 revenue of $9.8 billion (up 9.9% reported, 6.6% organic) and FY26 revenue of $36.4 billion, driven by new platforms and a 78% global rise in Cardiac Ablation Solutions. Danaher saw improving life‑sciences demand and mid‑teens growth in bioprocessing orders but delayed just over $100 million of revenue into next year and trimmed the upper end of its core revenue growth outlook to 4% from 6%. Hedge fund ownership fell for both names between Q4 2025 and Q1 2026, with a sharper decline for Danaher, underscoring differing conviction in each recovery story. » Altro su finance.yahoo.com

Medtronic has completed the acquisition of Scientia Vascular of Salt Lake City for $550 million. Scientia supplies guidewires and catheters for neurovascular procedures and complements Medtronic’s portfolio with access technologies for treating strokes and aneurysms. The purchase price is subject to customary adjustments and includes potential earn-out and milestone payments; the transaction is expected to only minimally dilute adjusted earnings per share in 2027 and to be accretive thereafter. » Altro su de.investing.com

Medtronic shares gained 5.76% after reporting quarterly results that beat expectations and confirmed a bullish doji candle. After the decline from the multi-year high in November 2025, attention now turns to resistance areas at 78.60–79.97 USD and 80.91–81.53 USD; a daily close above these levels would brighten the medium-term chart picture. Support lies at 75.75–76.59 USD; a close below could close the gap to 74.48 USD and allow a test of the low at 73.31 USD. » Altro su finanzen.net